Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
45.06 USD | +0.27% | +2.64% | -12.18% |
10/05 | Bristol-Myers Squibb Says Phase 3 Trial of Opdivo in Lung Cancer Fails to Meet Primary Endpoint | MT |
10/05 | Bristol Myers Squibb Cancer-Treatment Trial Misses Endpoint | DJ |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-12.18% | 9.13TCr | |
+29.98% | 68TCr | |
+30.34% | 59TCr | |
-3.52% | 36TCr | |
+18.59% | 33TCr | |
+4.07% | 28TCr | |
+16.21% | 24TCr | |
+9.66% | 21TCr | |
-6.83% | 20TCr | |
+7.09% | 17TCr |
- Stock Market
- Equities
- BMY Stock
- News Bristol-Myers Squibb Company
- Morgan Stanley Trims Price Target on Bristol-Myers Squibb to $40 From $41, Keeps Underweight Rating